US Pre-Market SEC Filings Roundup — April 13, 2026

13-04-2026

ChoiceOne Financial Services, Inc. issued a definitive proxy statement for its virtual Annual Meeting of Shareholders on May 20, 2026, at 8:00 a.m. ET, with a record date of March 31, 2026. Shareholders will vote on electing five director nominees (Keith D. Brophy, Michael J. Burke, Jr., Bruce John Essex, Jr., Steven T. Krause, Michelle M. Wendling) for terms expiring in 2029, advisory approval of executive compensation, and ratification of Plante & Moran, PLLC as independent auditors for the year ending December 31, 2026. As of March 31, 2026, 14,956,917 shares of common stock were issued and outstanding.

• ·Annual Meeting held exclusively via live webcast at www.virtualshareholdermeeting.com/COFS2026; access requires 16-digit control number from proxy.
• ·Proxy materials and Annual Report for year ended December 31, 2025 available at www.choiceone.bank/About/Investor-Relations/Proxy-Materials.
• ·Board consists of 15 directors divided into three classes; nominees for class with terms expiring in 2029.
• ·Voting requirements: plurality for directors, majority for advisory exec comp and auditor ratification.

13-04-2026

Willow Lane Acquisition Corp. filed a Form 425 disclosing social media posts on LinkedIn and X promoting its proposed business combination with Boost Run Holdings, LLC, pursuant to a Business Combination Agreement entered on September 15, 2025. The filing references a Registration Statement on Form S-4 containing a proxy statement/prospectus and urges shareholders to review SEC documents for details on the transaction involving Pubco (Boost Run Inc.) and merger subs. While highlighting potential benefits, it includes extensive forward-looking statements tempered by significant risks such as transaction failure, operational disruptions, and market uncertainties.

• ·Business Combination Agreement dated September 15, 2025
• ·Social media posts published April 10, 2026
• ·Filing date: April 13, 2026

13-04-2026

Alamar Biosciences is filing an S-1/A for an IPO offering 9,375,000 shares at a midpoint price of $16.00 per share, expecting net proceeds of approximately $133.2 million (or $154.1 million if underwriters' option for 1,406,250 additional shares is exercised in full), with total shares outstanding post-IPO at 64,890,799 (or 66,297,049). For the year ended December 31, 2025, total revenue grew 195% YoY to $74.2 million from $25.1 million in 2024, driven by product revenue surging 257% to $58.4 million, while gross profit expanded to $41.7 million; however, the company reported a net loss of $29.8 million (improved from $47.1 million in 2024), with operating expenses rising due to SG&A increasing 88% to $35.6 million amid ongoing R&D investments.

• ·1-for-2.418 reverse stock split effected on April 10, 2026.
• ·Proposed Nasdaq trading symbol: ALMR.
• ·Stock-based compensation expense increased to $2.9 million in 2025 from $0.9 million in 2024.
• ·Pro forma net loss per share for 2025: $(0.54) (unaudited).
• ·Weighted-average exercise prices: 2018 Plan options $3.18 (pre-2026) and $8.26 (post); warrants $3.55; phantom options $4.32 (pre) and $9.00 (post).

13-04-2026

IDEAYA Biosciences and Servier announced positive topline results from the Phase 2/3 OptimUM-02 trial in 1L HLA-A*02:01-negative mUM, where darovasertib + crizotinib met the primary endpoint with median PFS of 6.9 months vs. 3.1 months in the ICT arm (HR 0.42, 58% risk reduction, p<0.0001) and superior ORR of 37.1% vs. 5.8% (p<0.0001), including 5 complete responses vs. none. The combination showed a median DOR of 6.8 months, an early positive OS trend (immature data), and was generally well-tolerated with manageable safety profile, though Grade 3+ AEs included diarrhea, syncope, and hypotension, and treatment-related serious AEs were in the single-digit percent range. The company plans an NDA submission to the FDA in H2 2026 and additional data presentation at a 2026 medical conference.

• ·Trial cutoff date: January 23, 2026
• ·ICT arm: 76% (n=78) ipilimumab + nivolumab, 24% (n=25) pembrolizumab
• ·Treatment-related serious adverse events rate: single-digit percent in darovasertib + crizotinib arm
• ·OS data immature with early positive trend for darovasertib + crizotinib

13-04-2026

On April 9, 2026, Mark Keeley resigned as Chief Financial Officer Consultant of Mobile Global Esports, Inc. Brett Rosin, the Company's Chief Executive Officer, will serve as the principal accounting officer on an interim basis until a new Chief Financial Officer is hired. The filing discloses no details on the reasons for the resignation or any compensatory arrangements.

• ·Company trades as MGAM on OTC Pink Sheets
• ·Emerging growth company status confirmed
• ·Principal executive offices: 500 Post Road East, 2nd Floor, Westport, CT 06883

13-04-2026

Stephens Group, LLC filed a 13F-HR on April 13, 2026, disclosing its equity holdings as of March 31, 2026, with sole voting and investment power. Key positions include Energy Transfer LP at $105,080,722 (5,444,597 shares), Westrock Coffee Co at $34,467,683 (8,110,043 shares), CS Disco Inc at $29,783,134 (7,796,632 shares), and StubHub Hldgs Inc Class A at $2,175,876 (348,698 shares). No changes or performance metrics were detailed in the filing.

• ·Filing CIK: 0001427999
• ·Filer address: 100 River Bluff Drive, Suite 500, Little Rock, AR 72202
• ·All reported holdings held with sole voting and investment power (no shared or other power indicated)

13-04-2026

American States Water Company (AWR) reported 2025 diluted EPS of $3.37, up 6.3% from $3.17 in 2024 (GAAP) and 10.9% from adjusted $3.04, driven by new utility rates, management fees, construction activity, and lower interest at contracted services, while parent-level contributions were negative $0.09 per share. The company raised its quarterly dividend by 8.3% for the 71st consecutive year, achieved 13.3% ROE despite a 15.9% increase in average equity, and posted 7.7% 10-year CAGRs for both EPS and dividends. Key 2025 developments include CPUC approvals for $650M in capital investments and ASUS securing $29.4M in new projects.

• ·AWR debt rating A Stable; GSWC A+ Stable
• ·Institutional ownership ~85%
• ·Dividend yield 2.62% as of April 9, 2026
• ·Water utility adopted average rate base 5-year CAGR 11.3% through 2026
• ·GSWC retains authorized ROE 10.06% and 57% equity ratio through 2027
• ·Regulated utilities diverse supplier spending 30.8% exceeding CPUC 23% target for 13th year
• ·94% shareholder support for 2025 Say on Pay
• ·75% of CEO target total direct compensation at risk

13-04-2026

Minerva Gold Inc. entered a Letter of Intent on April 10, 2026, to acquire Taizhou Sentian Sanitary Ware Co., Ltd., a sanitary ware manufacturer owned by its new Sole Officer and Director Zhang Chengcheng, via issuance of common and preferred stock, with definitive agreement expected by May 31, 2026. Concurrently, Zhang Chengcheng acquired 5,000,000 shares (76.10% of 6,570,000 outstanding shares) for $264,600 cash, triggering a change in control, with prior officers Aftandil Aibekov and Meltem Alieva resigning and Zhang appointed as sole director and officer. This related-party transaction represents a strategic pivot from gold to bathroom fixtures manufacturing amid potential conflicts of interest.

• ·Taizhou Sentian founded in 2008, based in Taizhou, Zhejiang Province, China, with website cnsentian.com.
• ·Zhang Chengcheng, 36, CEO of Taizhou Sentian since 2023; prior roles include Quality Control Inspector at Cougar Shoes (2014-2016) and Head of Brand Development at Dongguan Hanghua Footwear / Jia Kuang Trading (2016-2023); Bachelor's in Electrical Engineering from University of Duisburg-Essen.

13-04-2026

GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.) filed an 8-K/A on April 13, 2026, amending its October 6, 2025 Initial 8-K to include audited financial statements of acquired GridAI Corp. from inception to September 30, 2025 (Exhibit 99.1), unaudited pro forma condensed combined balance sheet as of September 30, 2025, and pro forma statement of operations for the nine months ended September 30, 2025 (Exhibit 99.2), along with business overview and risk factors (Exhibit 99.3). The amendment provides financial information related to the completed share exchange agreement with GridAI stockholders. No specific financial metrics or period-over-period comparisons are disclosed in the filing narrative.

• ·Consent of independent auditor Macias Gini & O’Connell LLP (Exhibit 23.1)
• ·Registrant’s principal executive offices: 777 Yamato Road, Suite 502, Boca Raton, FL 33431
• ·Common Stock trading symbol: GRDX on The Nasdaq Stock Market LLC

13-04-2026

Sow Good Inc. entered into a Sales Agreement with Craft Capital Management, LLC, to offer and sell up to $100 million of its common stock through an at-the-market offering on Nasdaq. However, on April 7, 2026, the company received a Nasdaq notice stating it no longer complies with the $2.5 million minimum stockholders' equity requirement per Listing Rule 5550(b)(1), based on its Form 10-K for the year ended December 31, 2025. The company has until May 22, 2026, to submit a compliance plan, with a potential extension to October 4, 2026, but faces delisting risk if unresolved.

• ·Sales conducted as 'at the market offering' under Rule 415(a)(4), including direct sales on Nasdaq.
• ·Sales Agreement pursuant to Form S-3 (File No. 333-294799, effective April 9, 2025) and Prospectus Supplement dated April 13, 2026.
• ·Company not obligated to sell any shares; either party may suspend or terminate upon notice.
• ·Nasdaq compliance plan submission deadline: May 22, 2026; potential extension to October 4, 2026.

13-04-2026

Palo Alto Networks, Inc. (PANW) entered into Amendment No. 5 to its lease with SANTA CLARA PHASE III EFH, LLC for approximately 290,082 rentable square feet at Building E, 3000 Tannery Way, Santa Clara, CA, extending the lease term 144 months from August 1, 2028, to July 31, 2040, with options for two additional 72-month extensions to 2052. Base Monthly Rent begins at $1,087,807.50 ($13,053,690 annually) for the first Extension Term year, escalating annually up to $1,352,551.91 ($16,230,622.92 annually) in the final year, with full abatement of Base Monthly Rent for the first 12 months but other charges still due. The amendment includes a Work Letter for Tenant Improvements and confirms no defaults under the existing lease.

• ·Lease originally dated May 28, 2015; prior amendments on September 16, 2016; November 16, 2016; June 22, 2017; September 29, 2017.
• ·Options to extend: First Extension Period August 1, 2040 – July 31, 2046; Second Extension Period August 1, 2046 – July 31, 2052 (no Third Extension Period).
• ·Landlord notice address: c/o CBRE Investment Management, LLC, 200 Park Avenue, 20th Floor, New York, NY 10166.
• ·Tenant accepts premises 'as-is' subject to Tenant Improvements and Tenant Improvement Allowance per Work Letter.
• ·Mutual estoppels confirm no defaults, no offsets, no security deposit held as of April 8, 2026.
• ·Brokers: CBRE, Inc. (Landlord), Newmark (Tenant); commissions payable by Landlord.

13-04-2026

Angel Studios, Inc. (NYSE: ANGX) priced an underwritten public offering of 14,300,000 shares of Class A common stock at $2.10 per share, expecting gross proceeds of approximately $30 million before underwriting discounts and expenses. The underwriters received a 30-day option to purchase up to an additional 2,145,000 shares, with closing expected on April 13, 2026, subject to customary conditions. Proceeds will fund general corporate purposes, including capital expenditures and working capital.

• ·Roth Capital Partners acting as sole book-running manager; Maxim Group LLC and Texas Capital Securities as co-lead managers; Lake Street Capital Markets as financial advisor.
• ·Shelf registration statement on Form S-3 (File No. 333-291514) declared effective by SEC on December 4, 2025.
• ·Angel has achieved the highest audience satisfaction scores in the industry and the highest average domestic box office per title among all independent studios.

13-04-2026

Ameriguard Security Services Inc. (AGSS) disclosed that its subsidiary TransportUS Inc. (TUS) lost the Veterans Affairs Long Beach CA contract after 7.5 years, resulting in a 58% loss of projected 2026 revenue or approximately $9 million annually. The contract, valued at $20,928,228 over 3.5 years, was awarded to another California corporation, with transition occurring in April 2026. However, TUS retains two southern California contracts worth $3.8 million annually and plans to protest the award while bidding on others.

• ·Contract managed by TUS for 7.5 years
• ·Transition to new contractor during April 2026
• ·TUS plans to protest the award based on post-award information
• ·TUS continues to bid on other transportation contracts of equal value

13-04-2026

On April 10, 2026, Replimune Group, Inc. received a second Complete Response Letter (CRL) from the U.S. FDA regarding its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. This regulatory setback follows a prior CRL and was disclosed via a news release (Exhibit 99.1) under Regulation FD. No additional positive developments or financial impacts were reported.

• ·Filing submitted on April 13, 2026, reporting event from April 10, 2026
• ·Information in Item 7.01 and Exhibit 99.1 not deemed 'filed' under Section 18 of the Exchange Act

13-04-2026

RCI Hospitality Holdings, Inc. disclosed a cybersecurity incident at subsidiary RCI Internet Services, Inc., starting March 19, 2026, where personal information (names, contact details, dates of birth, SSNs, and driver's license numbers) of numerous independent contractors was accessed via an insecure direct object reference vulnerability on the IIS web server. The incident did not affect business operations, customer data, or financial systems, with remediation completed including enhanced multifactor authentication and disabled external access, and no material adverse effect expected as costs are covered by cybersecurity insurance. However, ongoing investigations may reveal additional impacts, with potential legal, reputational, regulatory, and financial risks.

• ·Incident discovered March 23, 2026; investigation concluded April 7, 2026.
• ·Unauthorized actor has not publicly disseminated the data.
• ·Company to notify affected parties and regulators.

13-04-2026

Comstock Holding Companies, Inc. (CHCI) announced the acquisition of the 6.77-acre Woodland Pointe office campus in Herndon, Virginia, and executed a full-campus lease with Peraton covering the existing 185,000-square-foot Class A office tower and a new 100,000-square-foot build-to-suit office building, totaling nearly 300,000 square feet upon completion. The deal positions Peraton to fully occupy the campus in the Dulles Technology Corridor to support its technology and national security operations. This transaction advances Comstock's Institutional Venture Platform with institutional co-investors.

• ·Woodland Pointe located at 2200 Woodland Pointe Avenue, Herndon, Virginia, south of Dulles Toll Road.
• ·Existing building is LEED Gold certified with 165-person conference facility, parking garage, and green spaces.
• ·Formerly North American headquarters of Volkswagen.
• ·Comstock founded in 1985; operates via CHCI Commercial Management and CHCI Asset Management subsidiaries.

13-04-2026

ALT5 Sigma Corp reported FY2025 revenue of $24,840, more than doubling YoY from $11,887 (+109%), driven entirely by the Fintech segment. However, gross margin declined to 41% from 48% amid surging SG&A expenses to $33,039 (up 163%), leading to an operating loss of $(22,851) versus $(6,923) prior year, while a massive $402,054 unrealized loss on cryptocurrency assets drove net loss to $(344,507) from $(7,568). Adjusted EBITDA deteriorated to $(15,429) from $(1,509), with Biotech operations discontinued.

• ·Fintech segment SG&A expense $16,370 in FY2025 vs $5,456 in FY2024.
• ·Corporate and other operating expenses $16,669 in FY2025.
• ·Income tax benefit $86,742 in FY2025 from continuing operations.
• ·Net loss from discontinued Biotech operations $(3,021) in FY2025 vs income $733 in FY2024.
• ·Depreciation and amortization $5,268 in FY2025 vs $3,401 in FY2024.

13-04-2026

Digital Ally, Inc. reported total net revenues of $13,754,155 for the year ended December 31, 2025, up 1.7% YoY from $13,519,152, driven by Entertainment segment growth to $8,653,398 (up from $7,763,761) and service revenues up 16.0% to $9,416,879; however, Video Solutions revenues declined to $5,100,757 from $5,755,391, product revenues fell 19.7% to $4,337,276, and gross profit margin compressed sharply to 10% from 23%. Operating loss narrowed to -79% of revenue from -84%, and net loss per share improved to $(17.23) from $(33,488.74), though net loss attributable to common stockholders was -49% vs. -147%.

• ·Video Solutions product revenues declined 40.7% YoY primarily due to competitive pressure, new competitor products, price competition, adverse market conditions from company's financial condition, and inventory constraints limiting backlog fulfillment.
• ·Entertainment product revenues declined 7.4% YoY due to reduced scope of primary ticket sales by TicketSmarter as management focused on higher-margin events.
• ·Sales to domestic customers (law enforcement/commercial) direct via sales force; international via distributors; repair parts/services handled internally.
• ·Entertainment segment product revenues from ticket sales (e.g., Country Stampede) and service fees via TicketSmarter.com.

13-04-2026

OriginClear, Inc. reported revenue growth of 55% YoY to $6,816,843 for FY 2025, with gross profit up 8% to $1,621,076 and operating loss narrowed to $3.3M from $6.2M, while total liabilities decreased 49% to $26,711,626 and shareholders' deficit improved to ($28.4M) from ($54.9M). However, cost of revenue surged 79% to $5,195,767, net loss from continuing operations was $14.0M (improved from $18.0M but still substantial), and common shares outstanding ballooned to 15.6 billion from 1.7 billion due to conversions and issuances. Discontinued operations showed a net income of $463,530 versus a prior loss.

• ·Registered trademarks in 2025: WATERPRENEUR (Serial 90471071), The Blue Gold (Intl. TM Class 041, Serial 97734240), WATER ON DEMAND (Serial 98099605).
• ·Derivative liabilities $12,127,995 as of Dec 31 2025 (down from $14,651,326).
• ·Net income from discontinued operations $463,530 in FY 2025 vs loss of $929,987 in FY 2024.

13-04-2026

EACO Corp reported strong Q2 FY2026 results with revenues of $117,836, up 17.7% YoY from $100,132, gross profit rising 22.8% to $36,227 (margin 30.7% vs 29.5%), and net income increasing to $9,797 from $6,763. For the six months ended February 28, 2026, revenues grew 17.9% to $228,789 and net income surged 40.0% to $19,117. The balance sheet improved with total assets at $239,057 (up 3.8%), cash at $5,140 (vs $728), and current liabilities down to $54,291 from $65,919; however, inventory rose to $91,327 from $83,980 and marketable securities fell to $24,929 from $30,375.

• ·Basic EPS $2.01 for three months ended Feb 28, 2026 (vs $1.39 YoY)
• ·Diluted EPS $3.90 for six months ended Feb 28, 2026 (vs $2.79 YoY)
• ·Operating cash flow $890 for six months 2026 (vs $(1,063) in 2025)
• ·Weighted average remaining lease term 3.2 years at Feb 28, 2026 (vs 2.8 years prior)

13-04-2026

AITX reported preliminary FY2026 revenue growth of 26% to $7.75M from $6.14M, with gross profit expanding 48% to $5.53M and gross margins improving to 71% from 61%, driven by cost discipline. Operating expenses remained flat at $17.5M, resulting in a $2.0M improvement in loss from operations. However, CEO Steve Reinharz noted revenue growth fell short of expectations amid a turbulent economy, though the company maintains focus on scaling to positive cash flow.

• ·Completed SOC 2 Type 2 audit, validating operations and internal controls.
• ·RAD solutions designed to deliver 35%-80% cost savings vs. traditional manned security.
• ·Robust sales pipeline with expanding opportunities across subsidiaries and industries including enterprises, government, transportation, critical infrastructure, education, and healthcare.

13-04-2026

Kailera Therapeutics, Inc., an advanced clinical-stage biotechnology company, filed an S-1/A registration statement on April 13, 2026, for its initial public offering, highlighting its diversified GLP-1-based pipeline for obesity treatment led by ribupatide, a once-weekly injectable GLP-1/GIP dual agonist in global Phase 3 KaiNETIC trials (doses up to 10 mg) with demonstrated weight loss of up to 23.6% at 12 weeks (8 mg dose) and 19.2% at 48 weeks (6 mg dose). The company is also advancing oral ribupatide (up to 12.1% weight loss at 26 weeks), KAI-7535 oral small molecule, and KAI-4729 tri-agonist, while qualifying as a smaller reporting company with annual revenue under $100 million and no off-balance sheet arrangements. Topline results from Phase 3 trials are expected in 2028, with no head-to-head trials against competitors and all candidates still in development.

• ·KaiNETIC-1 initiated December 2025; KaiNETIC-3 December 2025; KaiNETIC-2 January 2026; Phase 2b high-dose March 2026.
• ·Global Phase 3 trials evaluate ribupatide doses of 4 mg, 6 mg, 8 mg, 10 mg over 76 weeks; Phase 2b up to 20 mg over 48 weeks.
• ·Plans to initiate global Phase 3 for oral ribupatide as early as first half of 2027.
• ·Exclusive worldwide rights to product candidates outside Greater China.
• ·No off-balance sheet arrangements.

13-04-2026

E Fund Management Co., Ltd. filed its 13F-HR disclosing $3,365,841,983 in holdings across 489 positions as of March 31, 2026. Top positions include Apple Inc. ($181,728,360 value, 716,058 shares) and Broadcom Inc. ($71,097,233 value, 229,709 shares), with significant exposure to technology and biotech sectors including AXT Inc. ($71,949,729 value, 1,262,719 shares). No period-over-period changes are provided in the filing.

• ·Holdings as of 2026-03-31, filed 2026-04-13.
• ·Futu Holdings Ltd.: $35,030,390 value, 256,145 shares.
• ·Kanzhun Limited: $23,289,642 value, 1,739,331 shares.
• ·Cisco Systems Inc.: $20,339,831 value, 262,145 shares.
• ·Numerous biotech holdings including Apellis Pharmaceuticals Inc. (22,686 shares SOLE) and Arcturus Therapeutics (23,007 shares SOLE).

13-04-2026

Clear Channel Outdoor Holdings, Inc. (CCO) has filed a proxy statement for a special stockholder meeting on May 12, 2026, to approve a merger with Madison Merger Sub Inc., a subsidiary of Madison Parent Inc. (backed by Mubadala Capital and TWG Global), under which shareholders will receive $2.43 in cash per share of common stock. Support agreements from key shareholders, including affiliates of Legion Partners, Ares Management, PIMCO, and Arturo Moreno, cover approximately 48% of outstanding shares as of March 20, 2026, and the board unanimously recommends approval of the merger, advisory compensation, and adjournment proposals if needed.

• ·Record date for Special Meeting: April 6, 2026.
• ·Merger Agreement dated February 9, 2026.
• ·Special Meeting held virtually at www.virtualshareholdermeeting.com/CCO2026SM.
• ·Shareholders have appraisal rights under DGCL Section 262.

13-04-2026

Zhanling International Ltd reported a net loss of $7,687 for the three months ended February 28, 2026, slightly up 1% from $7,595 in 2025, and $26,866 for the nine months, up 11% from $24,161, driven solely by general and administrative expenses with no revenue. However, total assets grew significantly to $5,506 from $166 as of May 31, 2025, current liabilities decreased to $3,124 from $9,122, and stockholders' deficit improved to $(41,419) from $(48,231), supported by a massive dilution in shares outstanding to 3,441,000 from 73,200. Cash balances remained at $0, with all operating cash used of $38,204 offset exactly by financing advances from related and non-related parties.

• ·Basic and diluted EPS for nine months ended Feb 28, 2026: (0.01) vs (0.33) in 2025.
• ·Prepayments increased to $5,506 from $166.
• ·Due to related parties: $38,696 as of Feb 28, 2026 vs $38,285 as of May 31, 2025.
• ·No cash balances at beginning or end of periods; no interest or taxes paid.
• ·Common stock authorized: 500,000,000 shares, $0.001 par value.

13-04-2026

Vertiv Holdings Co announced the closing of the acquisition of BMarko Structures, LLC by one of its wholly-owned subsidiaries on April 13, 2026, via a press release furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). No financial terms or performance metrics were disclosed in the filing.

• ·Filing includes Items 7.01 and 9.01.
• ·Information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and not deemed incorporated by reference.

13-04-2026

RPC Inc. filed a DEFA14A proxy statement supplement seeking stockholder ratification of performance stock unit (PSU) grants to CEO Ben M. Palmer in 2025 (max 125,083 shares after TSR) and 2026 (max 154,080 shares after TSR) that exceeded the 2024 Stock Incentive Plan's 200,000 share annual individual limit when combined with restricted stock awards (159,000 in 2025; 192,500 in 2026), leaving only 41,000 and 7,500 shares available respectively. Similar ratification is requested for the Executive Chairman's 2026 PSU grant, alongside approval of Plan amendments to remove individual limits (Proposal 7). The action follows a March 20, 2026 stockholder demand letter alleging Plan violations and calling for rescission or ratification.

• ·Proposals 5, 6, and 7 require majority of shares present or represented and entitled to vote; abstentions count as votes against.
• ·Broker non-votes have no effect on Proposals 5, 6, or 7.
• ·PSU performance based on 3-year cumulative adjusted EBITDA; 2025 grant covers FY 2025-2027, 2026 grant covers FY 2026-2028.
• ·Demand letter received March 20, 2026; special committee formed to review.
• ·Grants dated January 28, 2025 and January 27, 2026.

13-04-2026

AdvanSix Inc. (NYSE: ASIX) announced the appointment of Patrick C. Day as Senior Vice President and Chief Financial Officer, effective April 27, 2026, reporting to President and CEO Erin Kane. Day, previously VP of Financial Planning and Analysis and Investor Relations at FMC Corporation, replaces interim CFO Christopher Gramm, who will continue as Vice President of Corporate Finance and Strategic Financial Planning & Analysis. The appointment is positioned as strengthening leadership for growth and value creation.

• ·Filing Date: April 13, 2026
• ·Appointment effective: April 27, 2026
• ·Day's education: Bachelor’s degree in finance from Elizabethtown College; Master’s degree in accounting and tax from the University of Connecticut

13-04-2026

Pershing Square Holdco, L.P. filed an S-1/A registration statement on April 13, 2026, for the PSUS IPO and PSUS Private Placement, which are expected to materially expand permanent capital AUM with PSUS as the flagship NYSE-listed vehicle pursuing the core investment strategy. The firm generates revenues from predictable management fees, including a quarterly HHH Base Management Fee of $3,750,000 and a 0.375% HHH Variable Management Fee, alongside performance fees with a Preferred Performance Fee allocation. HHH is advancing its diversified holding company strategy through the $2.1 billion Vantage Acquisition, agreed on December 17, 2025, and expected to close in Q2 2026, while past examples include raising $1.1 billion via PSVII in September 2021 for Universal Music Group; however, the strategy involves risks from concentrated portfolios and potential portfolio company resistance.

• ·Founded in 2003.
• ·HHH Transaction completed May 5, 2025.
• ·PSUS subject to 1940 Act restrictions including investment, leverage, derivative, and diversification requirements.
• ·In February 2024, expanded fee offset arrangement for PSH to reduce performance fees and increase demand for PSH shares.
• ·Investment in Chipotle initiated in 2016, leading to board changes and turnaround initiatives.

13-04-2026

News Corporation disclosed via 8-K its ongoing $1 billion stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock, with daily transaction disclosures required to the Australian Securities Exchange (ASX). The filing attaches Exhibits 99.1 and 99.2 containing ASX disclosures provided on respective dates noted therein. No specific repurchase transactions or amounts are detailed in the filing body.

• ·Filing date: April 13, 2026; Earliest event date: April 10, 2026
• ·Registrant: News Corporation (Delaware, Commission File No. 001-35769, EIN 46-2950970)
• ·Principal executive offices: 1211 Avenue of the Americas, New York, New York 10036

13-04-2026

Somnigroup International Inc. (NYSE: SGI) announced a definitive agreement to acquire Leggett & Platt, Incorporated (NYSE: LEG) in an all-stock transaction valued at approximately $2.5 billion, with LEG shareholders receiving 0.1455 SGI shares per LEG share and owning about 9% of the combined company on a fully diluted basis. The transaction, approved by both boards and expected to close by year-end 2026 subject to shareholder and regulatory approvals, will result in a combined company with approximately $11.2 billion in 2025 net sales, $1.7 billion adjusted EBITDA, and $1.1 billion operating cash flow, operating 175 manufacturing facilities across 36 countries with over 36,000 employees. Strategic benefits include continued vertical integration, expanded markets, reduced leverage, and immediate adjusted EPS accretion before synergies.

• ·Exchange ratio: 0.1455 shares of Somnigroup common stock per share of Leggett & Platt common stock
• ·Transaction does not require Somnigroup shareholder approval
• ·Leggett & Platt expected to operate as a separate business unit post-close, maintaining offices in Carthage, Missouri
• ·Karl Glassman to lead Leggett & Platt post-closing and assist with transition to new CEO within 12 months
• ·Nearly 50 years of collaboration between Somnigroup and Leggett & Platt

13-04-2026

National Healthcare Properties, Inc., a self-managed REIT focused on senior housing and healthcare real estate, filed Amendment No. 1 to its Form S-11 registration statement on April 13, 2026, to offer 38,500,000 shares of Class A common stock at an expected price of $13.00-$16.00 per share, with an overallotment option for 5,775,000 shares, aiming for listing on Nasdaq under 'NHP'. The company, formed in 2012 and electing REIT status since 2013, reported net losses attributable to common stockholders of $71.1 million in 2025 (improved from $203.5 million in 2024), but worsened from $86.1 million in 2023, highlighting ongoing losses amid high investment risks and ownership restrictions to maintain REIT qualification.

• ·Registrant classified as non-accelerated filer.
• ·Ownership limits: no more than 9.8% in value or number of shares of capital stock.
• ·Principal executive offices: 540 Madison Ave, 27th Floor, New York, NY 10022.
• ·Applied for listing on Nasdaq Global Select Market under symbol 'NHP'.
• ·Non-GAAP measures disclosed include FFO, Normalized FFO, EBITDA, Adjusted EBITDA, NOI, Cash NOI, and Same Store Cash NOI.

13-04-2026

On April 12, 2026, ImageneBio, Inc. entered into a Securities Purchase Agreement with institutional and accredited investors for a private placement of pre-funded warrants to purchase up to 5,770,335 shares of common stock at $5.199 per Warrant Share, expecting gross proceeds of approximately $30 million upon closing on or about April 14, 2026. Net proceeds will fund late-phase development readiness in atopic dermatitis and expansion of IMG-007 into additional indications including alopecia areata. The company agreed to file a registration statement for resale of Warrant Shares within three business days following August 1, 2026.

• ·Pre-funded warrants have exercise price of $0.001 per Warrant Share, exercisable immediately on cashless basis until fully exercised.
• ·Closing subject to customary conditions; securities issued under Section 4(a)(2) exemption with restrictive legends.
• ·Registration Rights Agreement includes cash penalties for registration failures.

13-04-2026

Leggett & Platt, Incorporated has entered into a Merger Agreement with Somnigroup International Inc., whereby a wholly-owned subsidiary of Somnigroup will merge with Leggett & Platt, with Leggett surviving as a subsidiary, and each share of Leggett common stock converted into 0.1455 shares of Somnigroup common stock. The transaction, unanimously approved by both boards, is expected to qualify as a tax-free reorganization and is subject to shareholder approval, regulatory clearances including HSR, NYSE listing, and no material adverse effects, with an outside date of January 13, 2027 (extendable to April 13, 2028 for regulatory delays). Termination fees include $64M payable by Leggett for superior proposals and $80M reverse fee by Somnigroup for regulatory failures.

• ·Exchange Ratio: 0.1455 shares of Parent common stock per share of Company common stock, with equitable adjustments for stock splits.
• ·Stock options, RSUs, and PSUs will be converted/assumed by Parent with terms adjusted by Exchange Ratio; PSUs with open periods deemed at maximum performance (200% of target).
• ·Company non-solicitation covenant allows superior proposal with 4-business day notice period and good faith negotiations.
• ·Outside Date: January 13, 2027, automatically extended up to April 13, 2028 if only regulatory conditions remain.

13-04-2026

Ayalon Insurance Comp Ltd. disclosed 13F-HR holdings as of March 31, 2026, totaling $489569 thousand across 61 positions. The portfolio is diversified in ETFs and stocks, with top holdings including iShares MSCI ACWI ETF (316575 shares, $43804 thousand), State Street Technology Select Sector SPDR ETF (324357 shares, $43107 thousand), and State Street SPDR S&P 500 ETF Trust (54596 shares, $35578 thousand). No period-over-period changes are provided in the filing.

• ·Portfolio heavily weighted towards ETFs (e.g., State Street Communication Services Select Sector SPDR ETF: 250101 shares, $27726 thousand)
• ·Individual stock holdings include Apple Inc (39358 shares, $9989 thousand), NVIDIA Corp (49603 shares, $8651 thousand), Microsoft Corp (17159 shares, $6352 thousand)

13-04-2026

Czech National Bank filed its 13F-HR report on April 13, 2026, disclosing 503 equity positions in US-listed securities totaling $15,224,214,623 as of March 31, 2026. Top holdings include Apple Inc. ($1,014,739,978 for 3,998,345 shares), Amazon.com Inc. ($554,099,003 for 2,660,484 shares), Alphabet Inc. Class A ($455,953,986 for 1,585,596 shares), Broadcom Inc. ($399,659,430 for 1,291,265 shares), and Alphabet Inc. Class C ($365,365,837 for 1,273,673 shares). No prior period data is provided in the filing for comparison.

• ·Additional notable holdings: Exxon Mobil Corp. (1,138,133 shares valued at $193,095,645), Berkshire Hathaway Inc. Class B (499,410 shares valued at $239,317,272), and AT&T Inc. (1,906,577 shares valued at $55,271,667).

13-04-2026

Conagra Brands, Inc. (NYSE: CAG) announced the appointment of John Brase as President and Chief Executive Officer effective June 1, 2026, succeeding Sean Connolly who will step down from his leadership roles and the Board on May 31, 2026. Brase, with over 35 years of experience including roles at The J.M. Smucker Co. and Procter & Gamble where he led a $6B business, will also join the Board. The transition is described as smooth, with praise for Connolly's decade-long leadership in transforming Conagra into a pure-play food company generating fiscal 2025 net sales of nearly $12B.

• ·Brase previously oversaw U.S. retail, international, and Away from Home businesses at Smucker
• ·Conagra headquartered in Chicago
• ·Media contact: Mike Cummins (312-549-5257)
• ·Investor contact: Matthew Neisius (402-240-3226)

13-04-2026

Palvella Therapeutics, Inc. increased its Board of Directors from six to seven members and appointed John Doux, M.D., as a Class III director effective April 13, 2026, with term expiring at the 2026 Annual Meeting of Stockholders. Dr. Doux, a board-certified dermatologist with extensive experience in healthcare investments and prior service on the Company's board pre-reverse merger, was granted an option to purchase 6,000 shares of common stock vesting over 36 months per the Director Compensation Policy. The Board determined Dr. Doux to be independent under Nasdaq rules, with no related party transactions or family relationships.

• ·Dr. Doux, age 57, previously served on the Company's board from 2019 to 2022 prior to its reverse merger.
• ·No arrangements or understandings pursuant to which Dr. Doux was selected as director.
• ·Dr. Doux served on boards of multiple biotechnology companies, including Ceptaris Therapeutics acquired by Actelion.

13-04-2026

Spyre Therapeutics announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for moderate-to-severely active ulcerative colitis, meeting the primary endpoint with a statistically significant reduction in Robarts Histopathology Index (RHI) score of 9.2 points (p<0.0001), alongside 40% clinical remission rate and 51% endoscopic improvement rate. SPY001 was well tolerated, with 14% of patients (6/43) experiencing any treatment-emergent adverse events and only one non-drug-related serious adverse event. Recruitment for Part A is closed, Part B enrollment is open, with proof-of-concept data expected mid-2026 for SPY002 and Q3 2026 for SPY003.

• ·One serious adverse event (chest pain in 68-year-old male with comorbidities, ruled out for MI, not drug-related).
• ·Most common AE: back pain (n=2).
• ·No drug-related AEs, no AEs leading to discontinuation, no AEs of special interest, no deaths.
• ·Conference call and webcast on April 13, 2026 at 8:00 a.m. ET.
• ·Part B induction data (all cohorts) on track for 2027.

13-04-2026

Allogene Therapeutics announced positive interim futility analysis from the pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation for LBCL, with 58.3% (7/12) MRD negativity in the cema-cel arm versus 16.7% (2/12) in the observation arm, representing a 41.6% absolute difference, and rapid median 97.7% ctDNA reduction at Day 45 compared to a 26.6% increase in the observation arm. Cema-cel was well-tolerated with no CRS, ICANS, or GvHD, infections at 16.7% in both arms, and 50% low-grade neurologic events in the cema-cel arm versus 8.3% in observation. However, data are from a small sample of 24 patients with primary endpoints (EFS, PFS, OS) still blinded, and the cema-cel arm had more aggressive baseline features (100% stage III-IV vs 83.3%, higher IPI scores).

• ·ALPHA3 trial powered to detect 50% reduction in EFS event risk; accrual complete by end of 2027; interim EFS mid-2027, primary EFS mid-2028.
• ·10/12 cema-cel patients managed entirely outpatient; contrasts with 70-90% hospitalization in broader CAR T experience.
• ·25% patients in each arm entered after partial remission to 1L therapy; DA-EPOCH-R most common 1L regimen (58.3% cema-cel vs 41.7% observation).

13-04-2026

PKO BP BANKOWY Universal Pension Society JSC filed a 13F-HR disclosing $213,887,622 in equity holdings as of March 31, 2026, across 13 positions all held with sole voting and sole investment discretion. Top holdings include Micron Technology Inc ($59,730,112), Freeport-McMoRan Inc ($31,021,439), and Uber Technologies Inc ($28,164,192). No period-over-period changes are provided in the filing.

• ·Filing submitted on April 13, 2026, for period ending March 31, 2026.
• ·All 13 positions designated as 'SH SOLE' (sole shared investment discretion, sole voting power).
• ·Filer headquartered at Chlodna 52, Warsaw, R9 00-872.

13-04-2026

Goldman Sachs Group Inc (CIK: 0000886982) filed an 8-K on April 13, 2026, covering Items 2.02 (results of operations and financial condition), 7.01 (Regulation FD disclosure), and 9.01 (financial statements and exhibits), with a file size of 3 MB indicating substantial attachments such as earnings materials. This filing occurs amid a flurry of over 80 Rule 424(b)(2) prospectus supplements and free writing prospectuses (FWPs) filed April 8-13 under shelf registration 333-284538, signaling active registered securities offerings. No specific financial metrics, period-over-period changes, improvements, or declines are detailed in the provided filing metadata.

• ·SIC: 6211 - SECURITY BROKERS, DEALERS & FLOTATION COMPANIES
• ·State of Incorporation: DE
• ·Fiscal Year End: December 31
• ·Business Address: 200 WEST STREET, NEW YORK NY 10282
• ·Shelf Registration: 333-284538